Daniel ChandramohanMBBS MSc PhD
Role within the MiP Consortium:Principal Investigator MA2 & MA8, Co-Investigator MA5
Current Appointment: Professor of Public Health at LSHTM
Areas of interest: Malaria, Meningitis
Prof Chandramohan is a clinical epidemiologist and graduated in medicine in 1975. He then worked as a primary care physician in India and Ethiopia (1976) followed by a period working in one of OXFAM's primary care projects in Zimbabwe that aimed to address the inequity in health care and health through comprehensive primary care andthen becamea district medical officer in Zimbabwe (1983).
His research career started as a research fellow at the London School of Hygiene and Tropical Medicine (LSHTM) in 1992, developing and validating the verbal autopsy method and tools to assess causes of adult deaths in developing countries. The verbal autopsy method is now widely used particularly by most of the demographic surveillance sites in Africa and Asia.
In 1996, he joined the malaria knowledge programme of the LSHTM funded by the UK DFID and started to work on diagnosis, treatment and chemoprevention of malaria. In 2008, his work in with the Malaria in Pregnancy Consortium started with 2 studies of malaria in pregnancy in India. He also works on meningitis vaccine (Ethiopia and Ghana), and micronutrient supplementation (Afghanistan).
He has organised the MSc Public Health in Developing Countries course at LSHTM for several years and has developed a new study module entitled "applying public health principles in developing countries".
His main research interest ranges from diagnosis, treatment and chemoprevention of malaria to drug resistance, micronutrients and surveillance. He is the principal investigator for 2 trials with the MiP Consortium.
Prevention strategy in India
Effective and safe interventions for prevention of malaria in pregnancy in India: an assessment of burden of malaria in pregnancy, implementability of a screening strategy and barriers to scaling up interventions.
A multi-centre trial to compare the safety and effectiveness of two new antimalarial drug combinations compared to standard therapy for the treatment of malaria in the second and third trimesters of pregnancy in India.